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DOI 10.1016/j.ccr.2011.08.012SUMMARYPrimary tumors have been shown to prepare distal organs for later colonization of metastatic cells by
stimulating organ-specific infiltration of bone marrow derived cells. Here we demonstrate that neutrophils
accumulate in the lung prior to the arrival of metastatic cells in mouse models of breast cancer. Tumor-
entrained neutrophils (TENs) inhibit metastatic seeding in the lungs by generating H2O2 and tumor secreted
CCL2 is a critical mediator of optimal antimetastatic entrainment of G-CSF-stimulated neutrophils. TENs are
present in the peripheral blood of breast cancer patients prior to surgical resection but not in healthy individ-
uals. Thus, whereas tumor-secreted factors contribute to tumor progression at the primary site, they
concomitantly induce a neutrophil-mediated inhibitory process at the metastatic site.INTRODUCTION
The leading cause of cancer related mortality is metastatic
spread of tumor cells to distant sites. Metastasis is a multistep
process consisting of intravasation, survival in the circulation,
extravasation, survival in and colonization of distant tissues.
The complexity of each step of the metastatic process makes
it highly inefficient overall and although large numbers of cells
disseminate from the primary tumor, only a small fraction of
these cells end up forming distant tumors. However rare,
disseminated tumor cells ultimately successfully formmetastatic
colonies and therefore present a critical therapeutic challenge.
Many tumor types are capable ofmetastasizing to distant sites
however the location of these sites varies considerably among
different primary tumors. Several studies have shown that the
site of metastasis may be determined by a specific gene expres-
sion pattern, or signature, in primary tumor cells that mediates
metastasis to specific distant organs (Gupta and Massague´,
2006). In addition, tumor induced changes in the microenviron-
ment of distal organs prior to colonization might make certain
tissues more receptive to colonization of migrating tumor cellsSignificance
Metastasis represents the final stage in cancer progression an
inated cells that are capable of colonizing distant organs and
peutic challenge. Our data shows that during the premetastatic
stimulated by the primary tumor accumulate in the lung. These
metastatic protection by eliminating disseminated tumor cell
continued influx of metastatic cells, infusion of exogenous ne
sents a potential therapeutic strategy for management of micr
300 Cancer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier In(Joyce and Pollard, 2009). Recent studies have suggested that
factors secreted from the primary tumormaymodulate the future
site of metastasis in a directed fashion (Erler et al., 2009). Bone
marrow derived cells are mobilized by the primary tumor and
directed to the future site of metastasis (Kaplan et al., 2005)
where they take part in the formation of a functional premeta-
static niche. All of these processes are likely working in concert
to determine the future site of metastasis.
Here we describe the accumulation and activation of neutro-
phils by the primary tumor during the premetastatic stage in
mouse cancer models. Induced by the primary tumor, these
tumor-entrained neutrophils (TENs) accumulate in the circulation
and the premetastatic lung. Neutrophils are short-lived leuko-
cytes that are part of the innate immune system. Owing to their
highly motile nature, neutrophils are quick to respond and pro-
vide the first line of defense against infections through phagocy-
tosis, extracellular degranulation and spreading of extracellular
traps (Hickey and Kubes, 2009). Driven by cytokines and chemo-
tactic factors, neutrophils are also recruited to sites of inflamma-
tion where they take part in the inflammatory process. The notion
that tumors and sites of inflammation, such as wounds, shared is the primary cause for cancer related mortality. Dissem-
forming metastases therefore present an important thera-
phase in multiple murine breast cancer models, neutrophils
neutrophils acquire a cytotoxic phenotype and provide anti-
s. Although the neutrophils are eventually outcompeted by
utrophils effectively blocks metastasis and therefore repre-
ometastatic disease.
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be viewed as wounds that will not heal (Dvorak, 1986) and as
such incite an inflammatory response by recruiting leukocytes
through the production of various cytokines and chemokines
(Coussens and Werb, 2002).
The tumor recruited leukocyte population is heterogeneous
and consists, in part, of tumor-associated neutrophils (TANs).
TANs were previously shown to have a protumorigenic effect at
the primary site by secreting protumorigenic factors, promoting
angiogenesis and suppressing immune responses (Pekarek
et al., 1995; Shojaei et al., 2008; Youn et al., 2008). Interestingly,
the protumorigenic effects of neutrophils were shown to be
TGF-b dependent and upon TGF-b blockade, neutrophils were
shown to switch from the ‘‘N2’’ protumorigenic phenotype to
the ‘‘N1’’ anti-tumorigenic phenotype (Fridlender et al., 2009).
Recent studies have also suggested a prometastatic role for
neutrophils in the premetastatic niche. High numbers Gr-1+
CD11b+ cells were shown to accumulate in the premetastatic
lungs of mice bearing highly metastatic tumors. The Gr-1
epitope is present on both Ly-6G+ cells that are exclusively
neutrophils (Daley et al., 2008) and Ly-6C+ cells in which the
epitope is expressed at higher levels on monocytes than neutro-
phils (Zhu et al., 2007). Although not formally demonstrated by
depletion of Gr-1+CD11b+ cells, this study suggests that
tumor-mobilized lung associated Gr-1+CD11b+ cells contribute
to the formation of a prometastatic niche by generating an
immunosuppressive environment with abnormal vasculature
(Yan et al., 2010). In another recent study it was shown that
G-CSF stimulated neutrophils and monocytes increase the
metastatic seeding of circulating tumor cells in the lungs and
that both G-CSF and BV8 contribute to the formation of lung
metastases. Furthermore, in one 4T1-cell derivative orthotopic
model (66Cl4), Ly-6G-specific depletion of neutrophils was
found to reduce the metastatic burden in the lungs (Kowanetz
et al., 2010).
Through careful depletion and adoptive transfer experiments,
we examine the role of TENs in a variety of breast cancer models
and relate our findings to their presence in the peripheral blood of
breast cancer patients.
RESULTS
Neutrophils Accumulate in the Premetastatic Lung
Orthotopically implanted 4T1 tumors spontaneously metasta-
size primarily to the lung whereas metastases to the liver, brain,
and bones are less frequent (Figure 1A) and arise much later (not
shown). To determine if transcriptional changes take place in the
lung prior to the arrival of metastatic cells that might modulate
the behavior of these cells, we performed mRNA microarray
analysis of lung and liver samples from sham-operated (ortho-
topically injected with PBS) versus tumor-bearing mice. We
found no significant differences in gene expression 3 days after
tumor engraftment. In contrast, the expression of 325 and 912
genes was significantly changed in the lung and liver, respec-
tively, of tumor-bearing mice 7 days after tumor engraftment
relative to sham-operated controls (Figure 1B). Of the 325 genes
significantly changed in the lung, 293 were lung-specific and
were not changed in the liver. Only a small number of tumor cells
(<10) were found in the lungs or the liver at this point suggestingCanthat tumor cell contribution to the expression array is negligible
(Figure 1C).
Several neutrophil-specific genes (such as cathelicidin and
lactoferrin) are acutely upregulated in the premetastatic lung
but not in the liver (Figure 1D) and although we cannot rule
out the possibility that some of the mRNAs in the array can
come from the parenchyma or microenvironment we specu-
lated that neutrophils are recruited to the premetastatic lung.
This hypothesis was confirmed by immunohistological staining
with the neutrophil specific antibody Ly-6G that showed an
increase in Ly-6G+ neutrophils in the lung by day 7 posttumor
engraftment (Figure 1E). Further immunohistochemical analysis
was performed on premetastatic lung tissue to test whether
acutely upregulated genes colocalize with neutrophils. As can
be seen in Figure 1F, MMP9 (upregulated 45-fold) colocalizes
with the neutrophil marker Ly-6G, as well as with other neutro-
phil markers such as cathelicidin (Figure S1A available online),
but not with the pan macrophage marker F4/80. Neutrophils
continue to accumulate in the lungs over a period of 28 days
and start accumulating in the liver on day 28 posttumor engraft-
ment (Figure 1E). The increase in lung neutrophils was also
found in athymic mice bearing other premetastatic xenografts
as well as in mice bearing MMTV-Wnt1 and MMTV-PyMT-
driven spontaneous mammary tumors prior to the appearance
of overt lung metastases. (Figures S1B and S1C). Interestingly,
we found that neutrophils do not accumulate in large numbers
in the premetastatic lungs (or the circulation) of mice bearing
the 4T1 derivative tumor 66Cl4 (Figures S1D–S1F; see also
Discussion).
Neutrophil Depletion in Tumor-Bearing Mice
In order to unequivocally determine the role of neutrophils in the
lung premetastatic site, we first established our ability to effi-
ciently deplete neutrophils in tumor bearing animals. Balb/c
mice were orthotopically injected with 4T1 cells and were then
treated with either control (IgG) or the neutrophil-specific
depleting antibody Ly-6G (Daley et al., 2008). Control mice
were sham-operated and treated with the control antibody
(IgG). Ly-6G antibody treated tumor-bearing mice show a
dramatic reduction in circulating neutrophil numbers from
43% in tumor-bearing mice treated with control IgG down to
2% (Figure 2A). Neutrophils are also dramatically depleted
in the primary tumor rim and lungs (Figures 2B and 2C). As
expected, we observed similar results when using the Gr-1
antibody for neutrophil depletion (not shown). Analysis of lung
associated CD11b+ cells shows a significant increase in
CD11b+MMP9+ cells (that are almost exclusively neutrophils,
note Ly-6G-MMP9 colocalization in Figure 1F) in the lungs of
tumor-bearing mice (Figure S2A) compared with sham-operated
mice. Upon neutrophil depletion there is a dramatic reduction in
lung associated CD11b+MMP9+ cells (neutrophils, Figure S2B)
but no significant effect on the CD11b+MMP9- population (Fig-
ure S2C). This observation suggests that lung associated
CD11b+ cell populations, other than neutrophils, are not dramat-
ically affected by neutrophil depletion. Interestingly, we found
no significant differences in the number of lung-associated
Ly-6C+ monocytes in either tumor-bearing mice or neutrophil-
depleted tumor-bearing mice compared to tumor free mice
(Figure S2D).cer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier Inc. 301
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Figure 1. Early Transcriptional Changes in the Premetastatic Lung and Liver
(A) Spontaneous metastatic progression from orthotopically engrafted luciferase-labeled 4T1 tumor cells to the lungs in syngeneic Balb/c mice.
(B) Venn diagram summarizing the transcriptional changes in the lung and the liver from sham operated versus 4T1 tumor bearing mice (n = 3 mice per group).
(C) Colony formation assay performed on lung and liver tissue from days 7 and 14 posttumor engraftment (n = 4).
(D) Top 10 upregulated genes in lung and liver expression array. Highlighted genes are expressed in myeloid cell lineages.
(E) Ly-6G immunohistochemistry performed on lung and liver tissues from tumor-bearing or sham-operated mice on day 7 posttumor engraftment. Graphs
depicting the number of neutrophils/ high power field in the lung and liver.
(F) Costaining of lung tissue from tumor-bearing mice on day 7 shows that MMP9 (green) colocalizes with Ly-6G (red on upper panel) but not with F4/80 (red on
lower panel). Error bars represent ± standard error of the mean (SEM) (**p < 0.01). See also Figure S1.
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Figure 2. Ly-6G Antibody Administration Depletes Neutrophils from the Circulation, the Primary Tumor, and the Premetastatic Lung
(A) Circulating Ly-6G+ neutrophils in 10 days posttumor engraftment in sham-operated and tumor-bearing mice treated with control IgG or Ly-6G antibody.
(B) Ly-6G immunohistochemistry performed on tumors from IgG or Ly-6G antibody treated mice.
(C) Ly-6G immunohistochemistry performed on lung tissue from sham operated mice and tumor-bearing mice treated with control IgG or Ly-6G antibody.
See also Figure S2.
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in the Premetastatic Lung
We next tested the long-term effects of neutrophil depletion on
spontaneous metastasis from synchronous mammary 4T1
tumors in syngeneic Balb/C mice. Neutrophil depletion in the
circulation was highly effective until day 14 posttumor engraft-Canment, after which neutrophil levels were not significantly different
in control or neutrophil depleted mice, perhaps due to enhanced
neutrophil release from the bonemarrow induced by the growing
tumor (Figure 3A). Importantly, metastatic seeding of the lung
takes place during the period of effective neutrophil depletion.
Although neutrophil depletion had no significant effect oncer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier Inc. 303
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tion of Lung Metastases
(A) Blood differentials showing neutrophils in control and
anti-Ly-6G treated tumor-bearing mice.
(B) Primary tumor growth in control (IgG, n = 9) and
neutrophil depleted (Ly-6G, n = 9) mice.
(C) Representative lung H&E images of control (IgG) and
neutrophil depleted (Ly-6G) mice by day 25 posttumor
engraftment.
(D) Metastatic foci size distribution in control (IgG) and
neutrophil depleted (Ly-6G) mice.
(E) Metastatic events per lung area in control (IgG) and
neutrophil depleted (Ly-6G) mice.
(F) Circulating Ly-6G+ neutrophils in tumor free (No tumor),
control (IgG treated, n = 5), and neutrophil depleted (anti-
Ly-6G treated, n = 5) MMTV-PyMT/MMTV-cMyc tumor-
bearing mice.
(G) Metastatic events per lung area in control (IgG) and
neutrophil depleted (Ly-6G) mice.
(H) Primary tumor growth in control (IgG) and neutrophil
depleted (Ly-6G) mice. Error bars represent ± SEM. See
also Figure S3.
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primary tumor (Figure 3B), neutrophil-depleted tumor-bearing
mice had increased metastatic burden compared with controls
(Figures 3C and 3E). A thorough histological examination shows
that although there is no significant difference in metastases size
distribution (Figure 3D) there is about a 3-fold increase in the
number of metastatic events (Figure 3E) suggesting that tumor
entrained neutrophils (TENs) inhibit seeding in the premetastatic
lung. Interestingly, neutrophil depletion had no significant effect304 Cancer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier Inc.on the number of circulating tumor cells (data
not shown) suggesting the effect of neutrophils
on seeding is confined to the premetastatic
site. Similar results were observed in 4T1 tumor
bearing athymic mice suggesting that the anti
metastatic effect of TENs is T cell independent
(Figures S3C–S3H). In addition, enhancement
of metastatic seeding in the lungs in neutro-
phil-depleted mice was similarly observed
when using the Gr-1 antibody, potentially de-
pleting not only Ly-6G+ neutrophils but also a
subset of Ly-6C+ monocytes (Figures S3C–
S3H). This observation suggests that in 4T1
tumor bearing mice, the antimetastatic effect
of neutrophils dramatically outweighs any con-
tribution by Ly-6C+ monocytes. The low rate of
spontaneous metastasis to other organs (liver
and brain) was unaffected by neutrophil deple-
tion but neutrophil accumulation at these sites
was at least 10-fold lower than the lungs (Fig-
ure 1E and data not shown).
Consistent with the observations made with
the 4T1 tumor model, neutrophil depletion in
MMTV-PyMT/MMTV-cMyc tumor bearing mice
results in enhanced metastatic seeding in the
lungs (Figures 3F and 3G). However, in this
model neutrophil depletion also resulted in a
modest enhancement in primary tumor growth(Figure 3H) therefore the increase in metastasis could be due
in part to the larger tumor volume at the primary site in thismodel.
In another widely used experimental model of metastasis we
injected tumor cells into the tail vein of tumor-bearing mice and
sham controls to examine the number of seeding tumor cells in
the lungs, with and without neutrophil depletion (Figures S3I–
S3L). Although the presence of a primary tumor increases the
seeding efficiency of tumor cells in the premetastatic lung
(perhaps due to previously described processes [Hiratsuka
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Figure 4. TENs But Not G-CSF Stimulated Neutrophils Attenuate the Formation of Experimental Metastases
(A) Representative images showing that transfer of TENs attenuates the formation of lung foci after tail-vein injection of tumor cells (n = 5 per group).
(B) Quantification of lung specific luciferase activity shows that TENs significantly delay the formation of lung foci.
(C) Representative images showing that transfer of G-CSF stimulated neutrophils has no effect on the formation of lung foci (n = 5 per group).
(D) Quantification of lung specific luciferase activity shows that G-CSF induced neutrophils do not delay the formation of lung foci.
(E) Multiple TENs transfers after introduction of tumor cells result in near complete ablation of lung foci formation (n = 4 per group).
(F) Quantification of lung specific luciferase activity shows that lung foci formation in mice treated with multiple TENs transfers is ablated. Error bars
represent ± SEM (*p < 0.05, **p < 0.01).
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neutrophil depleted tumor bearing mice (Figure S3K). Together,
our observations in both spontaneous and experimental models
of metastasis support the notion that although a subset of
Gr-1+Cd11b+ cells (that contain monocytes and neutrophils)
might play a prometastatic role (Yan et al., 2010), the net effect
of TENs is inhibition of tumor cell seeding in the premetastatic
lung.CanTENs Are Sufficient for Antimetastatic Protection
We sought to determine whether TENs are sufficient to provide
antimetastatic protection independent of T cell activity. To this
end, athymic mice were injected with 2 3 104 4T1 cells via the
tail vein to induce experimental metastases and then, 4 hr later,
these mice were treated with 5 3 106 TENs purified from 4T1
tumor-bearing mice. The transfer of TENs results in a significant
delay in the formation of lung foci (Figures 4A and 4B). Incer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier Inc. 305
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Tumor Cells by Initiating Physical Contact
(A) Coculture of 4T1 cells with neutrophils (Neut.) or a
mixture of lymphocytes and monocytes (L&M) purified from
sham-operated (Cont.) or 4T1 tumor-bearing (Tumor) mice.
(B) TENs in coculture with 4T1 or MCF7 cells allowing
physical contact or in a TransWell plate.
(C) Neutrophils purified from wild-type (Cont. Neut.) or
mammary tumor-bearing MMTV-PyMT mice in coculture
with 4T1 cells.
(D) Vascular permeability in lungs of sham operated (Cont.)
and tumor-bearing (Tumor) mice.
(E) Neutrophils purified from healthy human volunteers
(Healthy) or breast cancer patients (Patients) in coculture
with MDA-MB-231 cells.
(F) Time-lapse microscopy showing a coculture of GFP
labeled TENs (green) and 4T1 cells (red).
(G) Representative images showing cleaved caspase 3
activity (NucView 488) in 4T1 cells cultured alone (top) or in
coculture with TENs (bottom). GFP intensity as an estimate
for apoptosis in 4T1 cells cultured alone (No Neut.), with
control neutrophils (Cont. Neut.), or TENs (Tumor Neut.).
These experiments were repeated at least three times
with similar results. Error bars represent ± SEM (*p < 0.05,
**p < 0.01, ***p < 0.001). See also Figure S4, Movie S1, and
Movie S2.
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animals had no significant effect on the formation of lung foci
(Figures 4C and 4D). When TENs were transfused on 3 consec-
utive days, at 4, 24, and 48 hr after introduction of tumor cells,306 Cancer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier Inc.lung foci were nearly entirely ablated (Figures
4E and 4F). These observations suggest that
although tumor-naive, G-CSF induced neutro-
phils do not affect the formation of lung foci,
TENs can provide antimetastatic protection
in vivo and dramatically reduce the seeding of
disseminating tumor cells in the lungs.
TENs Acquire a Cytotoxic Phenotype
and Kill Tumor Cells
Because neutrophils are armedwith an arsenal of
toxic peptides andmolecules, we postulated that
TENsmight be able to kill tumor cells directly and
thereby provide antimetastatic protection. We
therefore tested the tumor-cell killing capacity
of TENs in vitro. Neutrophils were purified from
sham-operated and tumor-bearing mice and
cocultured with luciferase-labeled 4T1 cells (to
allow selective quantification) at a 20:1 neutrophil
to tumor cell ratio. This coculture ratio is probably
an under estimation of the actual in vivo ratio
because tumor bearingmice (by day 7 posttumor
engraftment) have 106 neutrophils/ ml of blood
and they have already accumulated in the lungs
in large numbers (Figure 1E) whereas at that
time there are <10 tumor cells in the lungs
(Figure 1C).
Although control neutrophils had no significant
cytotoxic effect, TENs were highly cytotoxic (Fig-ure 5). Such cytotoxicity was not observed when tumor cells
were cocultured with a mixture of lymphocytes and monocytes
purified from either tumor bearing or control mice. No killing
was observed when the neutrophils and the tumor cells were
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is necessary for neutrophil mediated tumor-cell killing (Fig-
ure 5B). A similar killing pattern was observed with MCF7 cells
cocultured with TENs from 4T1-tumor bearing mice (Figure 5B)
suggesting that this is a broader phenomenon. Furthermore,
neutrophils purified from C57/B6 mice bearing B16 melanoma
tumors, but not from control mice, gained the ability to kill both
B16 and 4T1 cells (Figures S4A and S4B).
To conclusively exclude the possibility that neutrophil cyto-
toxicity in mice bearing implantable tumors is a result of
a nonspecific antigraft immune response we evaluated neutro-
phil cytotoxicity in mice bearing spontaneous MMTV-PyMT
driven mammary tumors. As shown in Figure 5C, neutrophils
purified from PyMT-induced tumor bearing mice are highly cyto-
toxic. Furthermore, neutrophil entrainment was not a result of
a general response to wounding because neutrophils purified
from wounded mice were found to be noncytotoxic (Figures
S4C–S4E). Importantly, although large numbers of TENs accu-
mulate in the premetastatic lung, we found no gross histological
evidence for tissue damage (Figure S4F). Furthermore, using
Evans Blue staining we found no indication for increased micro-
vascular permeability in lungs from tumor-bearing mice
compared to controls (Figure 5D) suggesting that TENs can
discriminate between tumor cells and normal cells (i.e., the
lung endothelium) in vivo.
Finally, we wanted to ascertain whether the generation of
TENs is relevant to human disease.Whereas neutrophils isolated
from healthy human volunteers were noncytotoxic, neutrophils
isolated from newly diagnosed breast cancer patients (Fig-
ure S5A) prior to tumor removal or chemotherapy were highly
cytotoxic (Figure 5E) suggesting that neutrophil entrainment is
not unique to murine tumor models but also occurs during the
natural course of the human disease. Furthermore, although
premetastatic lung tissue samples from breast cancer patients
are unavailable, high myeloperoxidase staining in the metastatic
lung parenchyma (in 5/5 cases examined) suggests that neutro-
phils accumulate in the lungs of breast cancer patients (Fig-
ure S5B). Taken together, these observations support the notion
that processes similar to those seen in murine cancer models,
i.e., neutrophil accumulation, lung sequestration, and activation
also occur during the natural course of human disease.
Real Time Visualization of TENs Cytotoxicity
We then monitored the interaction between TENs and tumor
cells using time-lapse microscopy. As early as 60 min after their
addition, GFP labeled TENs can be seen converging on the
adherent 4T1 cells (red, Figure 5F). The neutrophils initiate phys-
ical contact with the tumor cell at which time the tumor cell
undergoes dramatic morphological changes (Figure 5F). To
ascertain whether the interaction between TENs and tumor cells
results in tumor cell apoptosis, tumor cells were labeled with a
Caspase 3 fluorescent substrate prior to the addition of TENs.
As can be seen in Figure 5G there were no Caspase 3 positive
cells (GFP positive) in the control culture whereas GFP positive
cells can be seen in the 4T1+TEN coculture. Quantification of
GFP intensity as an indicator of Caspase 3 activation shows
a dramatic increase in the presence of TENs but not in the
presence of control neutrophils (Figure 5G). Using time-lapse
microscopy we are able to show the TENs induced activationCanof Caspase 3 in tumor cells in real time (Movie S1). Control
neutrophils do not form prolonged interaction with tumor cells
and fail to activate Caspase 3 and induce apoptosis (Movie
S2). These data suggest that TENs inhibit tumor cell seeding in
the lungs by inducing apoptosis, however, the high rate of spon-
taneous apoptosis of incoming tumor cells in the lung capillaries
precludes direct assessment of tumor cell killing by TENs in situ.
TENs Cytotoxicity Is Mediated by Hydrogen Peroxide
Next we sought to characterize the mechanism by which neutro-
phils kill tumor cells. Neutrophils can generate reactive oxygen
species (ROS) through the activity of the NADPH oxidase
complex and induce cell death by an oxidative burst (Figure 6A).
Indeed, coculture of TENs with tumor cells in the presence of
apocynin, a specific inhibitor of the NADPH oxidase complex,
completely inhibits the neutrophil mediated tumor-cell killing
(Figure 6B). Addition of exogenous superoxide dismutase did
not inhibit cell death suggesting that superoxides per se are
not directly involved in cell killing. In contrast, catalase (that
converts H2O2 to H2O and O2) completely inhibits cell killing (Fig-
ure 6B). The presence of the hypochlorous acid scavenger,
taurine, did not reduce tumor-cell killing by stimulated neutro-
phils suggesting the killing is by H2O2 (Figure 6B). This notion
is further supported by the observation that TENs generate
more H2O2 than control neutrophils (Figure 6C). To gain further
insight into the killing mechanism we treated naive neutrophils
with PMA, a potent activator of H2O2 production. As expected,
PMA induced a dramatic increase in H2O2 production in naive
neutrophils (Figure 6D). Consistent with previous reports (Dalle-
gri et al., 1983) we found that when in coculture with 4T1 cells,
PMA-treated naive neutrophils become highly cytotoxic killing
close to 100% of tumor cells (Figure 6E). However, we found
that unlike TENs, PMA-stimulated neutrophils have the capacity
to kill tumor cells evenwhen separated by amembrane in a trans-
well system (Figure 6E). This result suggests that PMA stimulated
neutrophils spontaneously secrete H2O2 in levels high enough to
kill tumor cells via a mechanism that does not require physical
contact. Because TENs require physical contact for tumor cell
killing (Figure 5B) we hypothesized that rather than spontaneous
H2O2 release, physical contact triggers the secretion of H2O2 in
TENs. To test this hypothesis we measured H2O2 levels in the
supernatant of TENs cultured alone or in coculture with 4T1 cells.
We found that although TENs generate high levels of H2O2 (see
Figure 6C) they do not secrete detectable levels of H2O2 when
cultured alone (Figure 6F). Consistent with our hypothesis, we
were able to detect H2O2 in nM concentration in the supernatant
when TENs were cocultured with 4T1 cells, suggesting H2O2
secretion by TENs is triggered in the presence of tumor cells
(Figure 6F).
Finally, to test whether the process through which neutrophils
inhibit metastasis is also relevant in vivo we tested the effect of
apocynin on spontaneous metastasis. We show that apocynin
treatment enhances metastasis and that apocynin treated mice
developed spontaneous lung metastases earlier than control
mice (Figure 6G). These results suggest that neutrophils induce
tumor cell death through generation of ROS by the NAPDH
oxidase complex. However, it is the generation and contact
triggered release of H2O2 rather than superoxides or the H2O2
chlorine metabolite, hypochlorous acid that mediates killing.cer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier Inc. 307
A B
C
E F G
D
Figure 6. TENs Cytotoxicity Is Mediated through the NADPH Oxidase-H2O2 Pathway and Triggered by Physical Contact
(A) The NADPH oxidase complex—superoxides generated by oxidizing NADPH converted into H2O2 by cellular superoxide dismutase (SOD). Myeloperoxidase
(MPO) converts H2O2 to hypochlorous acid (HOCl). Apocynin inhibits the formation of the NADPH oxidase complex, catalase catalyzes the formation of H2O and
O2 from H2O2 and taurine eliminates HOCl.
(B) Coculture of 4T1 tumor cells with TENs in the presence of the apocynin, superoxide dismutase (SOD), or taurine.
(C) H2O2 production in purified control neutrophils (Naive) and TENs (Tumor).
(D) H2O2 production in naive neutrophils in the presence of PMA or vehicle control (Cont.).
(E) Naive neutrophils cocultured with 4T1 cells treated with vehicle (Cont.), or PMA allowing physical contact (PMA) or in a TransWell plate (PMA-TW).
(F) H2O2 concentration in the supernatant of TENs cultured alone (TENs) or in coculture with 4T1 cells (TENs + 4T1).
(G) Quantification of lung specific luciferase activity to followmetastatic progression in control (Cont. n = 5) and apocynin (Apo. n = 5) treated tumor-bearing mice
(Cont. n = 5). These experiments were repeated at least two times with similar results. Error bars represent ± SEM (*p < 0.05, **p < 0.01).
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What is the mechanism through which neutrophils are activated
by the primary tumor? 4T1 tumor bearing mice have been shown
to have high levels of serum G-CSF that may account for neutro-
phil accumulation (DuPre’ and Hunter, 2007). Indeed, in vivo308 Cancer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier InrhG-CSF administration induces a significant increase in circu-
lating and lung-associated neutrophils in tumor-naive animals
(Figures S5C–S5F). However, it does not induce a cytotoxic
neutrophil response in vivo (Figures 4C and 4D) or in vitro (Fig-
ure 7A). These observations suggest that G-CSF secretion is
sufficient for both accumulation in the circulation and lungc.
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further activation for the entrainment of their antimetastatic
behavior.
The expression array performed on premetastatic lungs
showed a 7.9- and 4.6-fold increase in CCR1 and CCR2 respec-
tively, both of which are expressed inmurine neutrophils (Reichel
et al., 2006 and Figure S5G). Because 4T1 tumors were shown to
secrete CCL2 and CCL5 (DuPre´ et al., 2007) that are potential
ligands for CCR2 and CCR1 respectively, we tested whether
these chemokines can induce neutrophil-mediated tumor-cell
killing. Addition of either mCCL2 or mCCL5 can stimulate naive
neutrophils and induce tumor cell killing in vitro suggesting that
both are sufficient for neutrophil entrainment (Figure 7A). This
observation is further substantiated by the fact that CCL2 and
CCL5 induce an increase in H2O2 production in naive neutrophils
(Figure 7B). Similarly, both hCCL2 and hCCL5 can stimulate
human neutrophils purified from healthy volunteers and induce
the killing of human MDA-MB-231 cells in vitro (Figure 7C).
Because CCL2 and CCL5 expression has been documented in
several human tumors (see for example Soria and Ben-Baruch
[2008]) this observation suggests that neutrophil entrainment
by tumor-secreted factors might also be relevant in human
malignancies. Moreover, we find that human chemokines such
as CCL3, CXCL1, CXCL12, and CXCL16 also have the capacity
of dramatically inducing neutrophil cytotoxicity (Figure S5H).
This observation further expands the scope of human malignan-
cies where neutrophil entrainment might be relevant.
We compared the expression profiles of TENs, GCSF-treated
CCL2, and CCL5-treated neutrophils all relative to naive neutro-
phils and the results are presented in Figures S5I and S5J. The
top 10 most highly regulated genes in TENs compared to naive
neutrophils were similarly altered in the GCSF treated neutro-
phils despite the GCSF treated cells having little activity in the
in vitro assay. CCL2 and CCL5 treated neutrophils, although
potently activated, have no transcriptional changes >2- fold
including the 10 genes altered in TENS and GCSF treated
neutrophils. From this analysis, we can conclude that GCSF
has the most potent effect on neutrophil transcriptional profiles
but the activating changes induced by CCL2 and CCL5 are likely
not transcriptional. Combined effects of GCSF + CCL2 or 5 also
has little effect above the GCSF profiles (Figures S5I and S5J)
consistent with this hypothesis.
CCL2 knockdown in tumors, with two independent shRNAs,
blocks neutrophil entrainment (Figures 7D and 7E) without
affecting accumulation (Figure 7F). Knockdown of CCL2 leads
to a reduction in both CCL2 and CCL5 levels in the circulation
(Figures 7G and 7H). CCL5 knockdown on the other hand is
insufficient to block entrainment perhaps due to redundancy
with CCL2. Indeed, CCL2 knockdown is shown to reduce
CCL5 levels in 4T1 tumor bearing mice consistent with this
notion (Figure 7H). Neutrophils accumulating in CCL2kd tumor-
bearing mice were not activated as evidenced by their reduced
H2O2 production when compared to neutrophils isolated from
mice bearing control tumors (Figure 7I).
To further understand the role of tumor secreted CCL2 on
tumor growth and metastasis in vivo, we compared the growth
and spontaneous metastasis of orthotopically implanted CCL2
knockdown (CCL2kd) and control 4T1 tumors. Consistent with
the protumorigenic properties attributed to CCL2 (LobergCanet al., 2007; Lu and Kang, 2009) we found that primary CCL2kd
tumors show growth retardation when compared to control
tumors (Figure 7J). However, we found that spontaneous metas-
tasis from the CCL2kd tumors occurs earlier (Figure 7K) suggest-
ing that these tumors have increasedmetastatic potential. Taken
together, these observations suggest that although CCL2 secre-
tion by the primary tumor has a beneficial effect and enhances
growth at the primary site, it is concomitantly capable of inducing
an antimetastatic neutrophil response and inhibiting tumor cell
seeding at a distant site. Furthermore, these observations sup-
port the notion that a specific tumor secreted factor, namely
CCL2, rather than a nonspecific host versus tumor immune
response, is an important mediator of neutrophil entrainment.
As demonstrated above, neutrophils express CCR2, however,
because CC ligands such as CCL2 are known to be promiscuous
in binding CC receptors, the possibility of neutrophil entrainment
through CC receptors other than CCR2 cannot be excluded.
As mentioned above, neutrophil depletion does not affect the
growth of the 4T1 primary tumors (Figure 3 and Figures S3E and
S3L), suggesting that although TENs are induced by the primary
tumor, neutrophils are not cytotoxic at the primary site. To gain
further insight into the different function of CCL2 at the primary
site and the premetastatic site we tested whether other tumor
secreted factors have the capacity to modulate TENs cytotoxic
activity. We found that TGF-b, which is known to be secreted
by 4T1 tumors (Zhang et al., 2008), dramatically inhibits TENs
cytotoxicity toward tumor cells (Figure 7L). This result is consis-
tent with previous observations showing that TGF-b blockade
induces neutrophil-specific cytotoxicity at the primary tumor
site (Fridlender et al., 2009). Because 4T1 tumors secrete
TGF-b, its activity in the vicinity of the primary tumor is high (Fig-
ure 7M) likely resulting in inhibition of TENs cytotoxicity.
However, at distant sites such as the premetastatic lung,
TGF-b activity is low (Figure 7M) and should permit TENs cyto-
toxicity providing a plausible explanation for the different effects
of CCL2 at the primary and the premetastatic sites.
DISCUSSION
In recent years, significant efforts have been directed at under-
standing events that take place during the metastatic process.
It has become clear that key events in the metastatic cascade,
such as migration, intravasation, extravasation, and re-initiation
at the future site of metastasis, are determined at least in part in
a cell autonomous manner (Gupta and Massague´, 2006). On the
other hand, tumor cells are surrounded by nonmalignant tumor
stroma, consisting of extracellular matrix components, bone
marrow derived cells, fibroblasts, and other cell types (McAllister
and Weinberg, 2010) and the function of these cells is modified
by the malignant cells to generate a favorable environment for
tumor initiation and progression (Polyak et al., 2009). The protu-
morigenic tumor-stroma interaction has consequences not only
on primary tumor growth but also on invasion and metastasis as
these processes have been found to be actively promoted by
stromal cells (Joyce and Pollard, 2009). Finally, tumor mobilized
bone marrow derived cells were shown to have protumorigenic
effects at the metastatic site where they promote seeding of
circulating tumor cells and support the formation of macrometa-
stases (Kaplan et al., 2005).cer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier Inc. 309
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Figure 7. Tumor-Secreted CCL2 Is Both Required and Sufficient for Neutrophil Entrainment
(A) Neutrophils purified from naive mice were cocultured with 4T1 cells in the presence or absence of mCCL2, mCCL5, and rhG-CSF.
(B) H2O2 production in neutrophils from naive mice in the presence or absence of mCCL2 and mCCL5.
(C) Neutrophils purified from healthy human volunteers were cocultured with MDA-MB-231cells in the presence or absence of mCCL2, mCCL5, and rhG-CSF.
(D) CCL2 and CCL5 expression in 4T1 cells transduced with a nontargeting shRNA (cont.), CCL2 specific shRNA (1 and 2), and CCL5 specific shRNA (1 and 2).
(E) Coculture of 4T1 cells with TENs purified from mice bearing control (Cont. shRNA), CCL2kd (1 and 2), or CCL5kd (1 and 2) tumors.
(F) Circulating Ly-6G+ neutrophils in sham operated (no tumor) and mice bearing control (Cont.) or CCL2kd tumors.
(G and H) Circulating levels of CCL2 and CCL5 in tumor free mice (no tumor), and in mice bearing control shRNA (Cont.) and CCL2kd (CCL2kd) tumors.
(I) H2O2 production in TENs purified from mice bearing control or CCL2kd tumors.
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and Metastasis
Our analysis of the earliest transcriptional events that take place
in the premetastatic lung indicated that neutrophils induced by
the primary tumor arrive early to this site. The contribution of
neutrophils to primary tumor growth and metastasis is some-
what controversial. Neutrophils have been shown to promote
primary tumor growth (Pekarek et al., 1995) and have a protu-
morigenic effect through enhanced angiogenesis (Nozawa
et al., 2006; Shojaei et al., 2008), increased degradation of the
ECM (De Larco et al., 2004), and immune suppression (Youn
et al., 2008). Furthermore, CD11b+ bone marrow derived cells,
a heterogeneous myeloid cell population, have been associated
with priming of the premetastatic lung and enhanced seeding of
circulating tumor cells (Erler et al., 2009; Yan et al., 2010) and
cells expressingMMP9 (upregulated 45-fold in the premetastatic
lung expression array; Figure 1D) were shown to potentiate the
formation of lung metastases (reviewed in van Kempen and
Coussens, 2002). In contrast, an antitumorigenic role has been
observed following immunologic (Hicks et al., 2006) or cytokine
activation (Colombo et al., 1992) as well as through blockade
of TGF-b (Fridlender et al., 2009).
To unequivocally assess their contribution, neutrophils were
depleted using the Ly-6G antibody shown in previous studies
to effectively and specifically deplete neutrophils (Daley et al.,
2008). Our data shows that in the absence of neutrophils, the
size distribution of lung metastases is not significantly changed
whereas the number of metastatic events is significantly in-
creased suggesting that neutrophils limit the number of circu-
lating tumor cells that can seed the lungs productively. We
also found that although the presence of a primary tumor
increases the seeding efficiency of circulating tumor cells when
compared to tumor-free mice, depletion of neutrophils results
in a further increase in seeding efficiency. In the context of tissue
injury, neutrophil depletion was found to indirectly lead to a
reduction in the number of macrophages present at the sight
of injury (Daley et al., 2008). However, we found no evidence
for increased numbers of monocytes/macrophages in the pre-
metastatic lung of tumor bearing animals relative to controls
and no changes in monocyte/macrophage numbers were de-
tected following neutrophil depletion. These results suggest
that the observed effects on metastatic seeding are primarily
attributable to neutrophils rather than to other cell populations.
The dramatic accumulation of antimetastatic TENs in the lungs
seemingly contradicts the fact that the lungs are the major site
of metastasis from the mammary fat-pad. However, although
TENs contribute to the inefficiency of metastatic seeding in the
lungs, this protective mechanism eventually fails and metastatic
growth ensues. Interestingly, neutrophil depletion did not in-
crease the metastatic burden in other tissues such as the liver
in the 4T1 model. However, in our hands we very rarely saw
spontaneous metastasis to tissues other than the lungs in either
IgG treated or neutrophil depleted mice. Thus, although neutro-(J) Primary tumor growth in control (n = 5) and CCL2kd (n = 5) tumor-bearing mi
(K) Lung-specific luciferase activity measuring metastatic progression to the lung
(L) Coculture of TENs and 4T1 cells in the presence or absence of TGF-b.
(M) Phosphorylation of Smad2 in normal lung (Cont. lung), premetastatic lung (Tum
times with similar results. Error bars represent ± SEM (*p < 0.05, **p < 0.01). See
Canphils have no obvious protective effect in this setting, this idea
still needs to be tested in a model where there is a more reliable
spontaneous rate of metastasis to other organs in order to draw
firm conclusions.
TENs have cytotoxic properties and unlike tumor associated
neutrophils (TANs), they are not necessarily associated with
a specific organ but are circulating in the periphery. TENs are
CD11b+Ly-6G+ cells, generate increased amounts of H2O2 and
are identified in cancer patients and tumor-bearing mice. These
features are common the both TENs and granulocytic myeloid
derived suppressor cells (G-MDSCs) (Kusmartsev and Gabrilo-
vich, 2006; Youn et al., 2008) and raise the interesting possibility
that TENs might also have immune suppressive qualities or
alternatively represent a distinct subpopulation of cells. Through
depletion experiments, however, we show that the net contribu-
tion of Ly-6G+ neutrophils is antimetastatic outweighing any
prometastatic effect that might result from immune suppression
by these cells.
Kowanetz et al. (2010) have shown recently that simultaneous
depletion of both Ly-6G+ neutrophils and Ly-6C+ monocytes
reduce spontaneous metastasis in a variety of tumor models
including 4T1. Such a result could be consistent with the results
presented here assuming a strongly prometastatic role of Ly-6C+
monocytes, which would counteract the effects of neutrophil
depletion. As discussed above, specific depletion of neutrophils
with the Ly-6G antibody is required to make a definitive assess-
ment and this experiment was performed by Kowanetz et al.
(2010) only in 66Cl4 tumors where metastatic burden was re-
ported to be reduced by 35%. 66Cl4 tumor-bearing mice
however are observed to have very few circulating and lung
associated neutrophils compared with controls (Figures S1D–
S1F), in agreement with Kowanetz et al. (2010) (see Figure 1C
and Figure S2F) and with previous reports (Pande et al., 2009).
These observations suggest that the antimetastatic effect of
neutrophils is not evident in the 66Cl4 model simply because
of insufficient neutrophil accumulation.
Neutrophil Accumulation and Entrainment
Under normal circumstances, neutrophils play a crucial role as
a component of the innate immune system fighting infections
and taking part in the inflammatory process. As demonstrated
above, neutrophil function can be modulated by the primary
tumor and an increase in lung associated neutrophil numbers
can be seen in several tumor models during the premetastatic
phase. Administration of G-CSF was previously shown to be
sufficient for neutrophil accumulation (Molineux et al., 1990)
and is in fact currently used successfully as a therapy for in-
creasing the number of circulating neutrophils in patients with
neutropenia (Metcalf, 2010). The accumulation of large neutro-
phil numbers in tumor-bearingmice is therefore probably caused
by colony stimulation factor secreted by the primary tumor
(DuPre’ and Hunter, 2007). Our data shows that G-CSF adminis-
tration is not only sufficient for neutrophil accumulation but isce.
s in mice bearing control or CCL2kd tumors.
or lung) and the primary tumor. These experiments were repeated at least two
also Figure S5.
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the absence of a tumor. This observation suggests that neutro-
phils are not actively directed to the premetastatic lung by the
primary tumor but instead, an increase in circulating neutrophils
is passively responsible for the increase in lung-arrested neutro-
phils. Still, our data shows that G-CSF stimulated neutrophils
require further activation in order to acquire a cytotoxic
phenotype.
In the 4T1 model, we have shown that secretion of CCL2 by
the primary tumor is involved in neutrophil entrainment. Our
data and that of others suggest that CCL2may have a protumori-
genic effect at the primary site and that CCL2 blockade reduces
tumorigenesis (Loberg et al., 2007; Lu and Kang, 2009). Further-
more, systemic CCL2 blockade was recently shown to reduce
both tumor growth and metastasis a NSCLC tumor model in a
T cell dependent manner (Fridlender et al., 2011). CCL2 was
further found to play a prometastatic role in a process mediated
by inflammatory monocytes (Qian et al., 2011). Our data shows
that reduced CCL2 expression by the primary tumor results in
enhancedmetastatic seeding in a breast cancer model in a T cell
independent manner. These data highlight the complexity of the
host response to chemokines likely due to the many different cell
populations that respond to these factors.
The role of chemokines in human disease is similarly complex.
Several studies have shown that CCL2 has a protumorigenic
effect and that high CCL2 serum levels in cancer patients are
associated with advanced disease and a poor prognosis (Soria
and Ben-Baruch, 2008). Conversely, other clinical studies
show that high CCL2 levels are associated with a better prog-
nosis for breast cancer patients (Dehqanzada et al., 2006) and
a prolonged overall survival in pancreatic, gastric and colon
cancer patients (Monti et al., 2003; Tonouchi et al., 2002; Wata-
nabe et al., 2008). These latter studies are consistent with our
data and provide evidence for the relevance of CCL2 expression
to human disease. However, we also show that chemokines
other than CCL2 can stimulate a cytotoxic response in naive
human neutrophils (Figure S5H) an observation that suggests
that other chemokines might be involved in neutrophil entrain-
ment in human disease. We show that hCXCL12 (SDF-1) is twice
as potent as hCCL2 in activating human neutrophils. 4T1 tumors
do not express high levels of CXCL12, however, induced
CXCL12 expression in 4T1 cells results in reduced tumor growth
and reducedmetastasis (Williams et al., 2010). Furthermore, high
CXCL12 expression in breast cancer patients was found to be
strongly associated with a better prognosis (Mirisola et al.,
2009). As many of the chemokines tested are involved in inflam-
matory processes it seems that cytotoxic neutrophils with anti-
metastatic properties may also be generated during states of
systemic inflammation. Whether the antitumorigenic/antimeta-
static effect of CXCL12 or any other inflammatory chemokines
associated with better prognosis is mediated through the activa-
tion of neutrophils remains to be explored.
TGF-b Blocks Neutrophil Cytotoxicity
Neutrophil depletion in 4T1 tumor-bearing mice has no signifi-
cant effect on primary tumor growth whereas stimulating metas-
tasis suggesting that the primary tumor is protected from TENs
cytotoxicity. Neutrophils were previously shown to have a cyto-
toxic effect at the primary site, however, this N1 phenotype was312 Cancer Cell 20, 300–314, September 13, 2011 ª2011 Elsevier Inmanifested only when TGF-b signaling was blocked suggesting
that the so-called N2 protumorigenic neutrophil phenotype is
maintained at the primary site by exposure to TGF-b (Fridlender
et al., 2009). As demonstrated here, the situation at the meta-
static site is considerably different. Neutrophils arrive early at
the premetastatic site prior to the arrival of detectable metastatic
tumor cells and are activated in response to chemokines CCL2/5
(and perhaps others) secreted by the primary tumor. These
neutrophils are not exposed to the inhibitory effect of tumor
secreted TGF-b, acquire an anti-tumorigenic N1 phenotype
and are capable of killing metastatic cells. This process is inde-
pendent of activated T cells because it is observed in both immu-
nocompetent and athymic mice. Thus CCL2 secreted by the
primary tumor may act as a double-edged sword, promoting
growth of the primary tumor where TGF-b activity is high and
neutrophil killing is inhibited, whereas at the same time inducing
a neutrophil mediated antimetastatic response in the lung where
TGF-b activity is lower. We predict therefore that advanced
metastatic disease would be refractory to neutrophil killing due
to high TGF-b levels in larger metastatic masses but that
TGF-b blockade prior to adoptive transfer of TENs might
enhance the killing activity. Such predictions can now be readily
tested experimentally.
Our data suggests that during the natural course of cancer
progression, a unique population of cytotoxic neutrophils is
generated. These neutrophils are entrained by the primary tumor
and exert their cytotoxic activity in distant tissues thereby pro-
viding antimetastatic protection. Neutrophil entrainment con-
sists of two crucial events: neutrophil accumulation and chemo-
kine induced activation. Both are driven by tumor-secreted
factors that are necessary for optimal tumor growth. Unfortu-
nately, the antimetastatic protection provided by TENs is not
complete as eventually tumor cells outcompete TENs and form
metastases. Our results however suggest a means of entraining
neutrophils to suppress metastatic tumor cell growth that may
be exploited therapeutically in adoptive transfer procedures
like those described here for the management of micrometa-
static disease.
EXPERIMENTAL PROCEDURES
Animals
Balb/c, C57/B6, FVB, and Balb/c-Ubc-GFP mice were purchased from
Taconic, Jackson Laboratory, and Harlan. MMTV-Wnt1 mice were a kind gift
from Dr. Harold Varmus. MMTV-PyMT mice were a kind gift from Dr. Johanna
Joyce. MMTV-PyMT MMTV-cMyc mice were a kind gift from Dr. Jacqueline
Bromberg. All experiments involving animals were approved by MSKCC’s
Institutional Animal Care and Use Committee (IACUC).
Cell Lines
4T1, B16-F10, Lewis Lung, MCF7, and MDA-MB-231 cell lines were
purchased from the ATCC. The human 4175 (LM2) cell line was a kind gift
from Dr. Joan Massague´ and the mouse 66Cl4 cell line was a kind gift from
Dr. Yibin Kang. CCL2 and CCL5 knockdown 4T1 cells were generated by len-
tiviral transduction with CCL2 and CCL5 specific shRNAs from the SKI shRNA
lentiviral collection. 4T1 and 4175 cells were orthotopically injected into the
mammary fat pad. B16-F10 and LLC cells were injected intradermally. Sham
operated mice were orthotopically injected with PBS.
Neutrophil Depletion
Neutrophil depletion was achieved using daily intraperitoneal injections of
12.5 mg Rat anti-Gr-1 antibody (BD) or Rat anti-Ly-6G antibody (BD) startingc.
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antibodies were administered twice daily. Control mice were injected with
12.5 mg Rat isotype control (BD). Neutrophil depletion was monitored by
manual blood differentials and FACS analysis.Colony Formation Assay
Female nude mice (n = 4) were orthotopically injected with 53 106 puromycin
resistant 4T1 cells. On days 7 and 14 posttumor engraftment the mice were
sacrificed and perfused with PBS. The lungs and livers were removed, washed
with PBS, and dissociated with Collagenase A (Roche). The single cell suspen-
sion was then plated onto puromycin containing media and selected for
14 days. Colonies were stained with Methylene-Blue and counted manually.
This experiment was repeated two times with similar results.Mouse Neutrophil Purification
Whole blood was collected by cardiac puncture using heparinized (Sigma)
syringe. The blood was diluted with PBS-BSA (0.5%) and subjected to a
discontinuous Histopaque (Sigma) gradient (1.077 and 1.119). Neutrophils
were collected from the 1.077-1.119 interface, lymphocytes and monocytes
collected from the plasma-1.077 interface. RBCs were eliminated by hypo-
tonic lysis. The cells were washed twice with PBS-BSA and resuspended in
OptiMEM (Invitrogen) 0.5% FBS in a final concentration of 2 3 106 cells/ml.
Neutrophil purity and viability were determined visually and were consistently
>98%.Human Neutrophil Purification
Approval was obtained from the institutional review board of Memorial Sloan-
Kettering Cancer Center. Blood samples were collected from healthy volun-
teers or from patients who were already having blood drawn for presurgical
testing. Patients were consented accordingly as part of the approved protocol.
Heparinized blood (20 U/ml final) was mixed with an equal volume of Dextran
500 (3% in saline). The leukocyte-rich supernatant was layered on top of
histopaque 1077 (Sigma) and centrifuged. Neutrophils, collected in the pellet
fraction, were resuspended in 0.2% hypotonic buffer to remove contaminating
erythrocytes. Neutrophils were than washed three times in HBSS and resus-
pended in RPMI+FCS 2%.In Vitro Killing Assay
Luciferase labeled cells (5000/well) were plated on a 96-well in OptiMEM 0.5%
FBS (mouse neutrophils) or RPMI 2% FBS (human neutrophils). Four hours
later, purified neutrophils (100,000/well for mouse neutrophils and 5000 for
human neutrophils) were added to the plated tumor cells and cocultured over-
night. Chemokines or inhibitors (apocynin [100 mM], catalase [1000 u/ml],
superoxide dismutase [1000 u/ml], taurine [50 mM], and PMA [50 ng/ml] all
from Sigma) were added to the culture immediately after neutrophils were
added. Following overnight incubation, luciferase activity wasmeasured using
the Clarity (Bio-Tek) microplate luminescence reader. In vitro killing experi-
ments were repeated at least three times.Neutrophil Transfer
Female nudemicewere injectedwith 23 104 luciferase labeled 4T1 cells to the
tail vein. Four hours later, the mice were injected with 5 3 106 TENs or G-CSF
stimulated neutrophils into the tail vein. Control mice were injected with
vehicle. Formation of lung metastases was monitored using the IVIS-200
optical in vivo imaging system. Neutrophil transfer experiments had at least
five mice per group and were repeated three times with similar results.Chemokine Administration
rhG-CSF (Neupogen, Amgen) was administered daily (250 mg/kg/day) subcu-
taneously for 4 consecutive days. In vitro neutrophil stimulation; naive mouse
were cocultured with tumor cells in the presence of mCCL2, mCCL5 (R&D),
rhG-CSF (20 ng/ml), or with TGF-b (200 pM, R&D). Human neutrophils purified
from healthy volunteers were stimulated in vitro with hCCL2, hCCL3, hCCL4,
hCCL5, CXCL1, CXCL12, and CXCL16 (R&D at 100 ng/ml) or with rhG-CSF
(20 ng/ml).CanStatistical Analysis
For statistical analysis, the data is presented as mean ± SEM and were
analyses using Student’s t tests. Differences were considered significant
when p < 0.05.
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